Literature DB >> 16422972

Duration of action of sildenafil citrate in men with erectile dysfunction.

Clive Gingell1, Stefan R Sultana, Maria B Wulff, Sam Gepi-Attee.   

Abstract

INTRODUCTION: Viagra (sildenafil citrate) has a rapid onset of action for the treatment of erectile dysfunction (ED). However, its duration of action has not been thoroughly investigated. Practical knowledge of the time window available for sexual intercourse would be valuable for couples planning sexual activity. AIM: We investigated the duration of action of sildenafil in men with ED.
METHODS: This was a double-blind, randomized, placebo-controlled, four-way crossover study of 16 men, mean age of 55 years (range, 36-68 years) with ED of no known organic cause. Participants received oral sildenafil (100 mg) or placebo 1, 8, or 12 hours before visual sexual stimulation (VSS). Measurements included the duration of erections of >or= 60% rigidity, assessed by penile plethysmography (RigiScan), and the proportion of sildenafil responders, defined as patients with erections of >or= 60% rigidity for >or= 4 minutes and >or= 50% improvement over erections achieved in their placebo arm. Self-assessed duration of grade 3 (hard enough for penetration) or grade 4 (fully hard) erections was also recorded.
RESULTS: At 1, 8, and 12 hours after dosing with sildenafil, the mean duration of erections with >or= 60% rigidity was 26, 11, and 8 minutes, respectively, compared with only 3 minutes after placebo dosing (P < 0.05). However, the mean duration of self-assessed erections was 33, 23, and 16 minutes, respectively, compared with 7 minutes after placebo dosing (P < 0.05), and was greater than that assessed by RigiScan. Of the 69% sildenafil responders at 1 hour, 82% responded at 8 hours and 45% responded at 12 hours after sildenafil administration.
CONCLUSION: Sildenafil improved objective and self-assessed erectile function in men with ED, and the duration of action of sildenafil was longer than that previously reported. These data suggest that sildenafil may be effective in a significant proportion of men with ED up to 12 hours after being taken.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16422972     DOI: 10.1111/j.1743-6109.2004.04026.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  9 in total

1.  Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: results from a randomized, open-label study.

Authors:  K Hatzimouratidis; J Buvat; H Büttner; P A S Vendeira; I Moncada; M Boehmer; C Henneges; F G Boess
Journal:  Int J Impot Res       Date:  2014-05-01       Impact factor: 2.896

2.  Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia.

Authors:  Esref O Guven; Mevlana D Balbay; Kilciler Mete; Ege C Serefoglu
Journal:  Int Urol Nephrol       Date:  2008-07-22       Impact factor: 2.370

Review 3.  Avanafil for treatment of erectile dysfunction: review of its potential.

Authors:  Ryan M Burke; Jeffery D Evans
Journal:  Vasc Health Risk Manag       Date:  2012-08-29

Review 4.  Future prospects in the treatment of erectile dysfunction: focus on avanafil.

Authors:  Amjad Alwaal; Raed Al-Mannie; Serge Carrier
Journal:  Drug Des Devel Ther       Date:  2011-10-18       Impact factor: 4.162

5.  An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy.

Authors:  Wen-Jun Bai; Hong-Jun Li; Yu-Tian Dai; Xue-You He; Yi-Ran Huang; Ji-Hong Liu; Sebastian Sorsaburu; Chen Ji; Jian-Jun Jin; Xiao-Feng Wang
Journal:  Asian J Androl       Date:  2015 Jan-Feb       Impact factor: 3.285

Review 6.  Sildenafil 4.0-Integrated Synthetic Chemistry, Formulation and Analytical Strategies Effecting Immense Therapeutic and Societal Impact in the Fourth Industrial Era.

Authors:  Andreas Ouranidis; Anastasia Tsiaxerli; Elisavet Vardaka; Catherine K Markopoulou; Constantinos K Zacharis; Ioannis Nicolaou; Dimitris Hatzichristou; Anna-Bettina Haidich; Nikolaos Kostomitsopoulos; Kyriakos Kachrimanis
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-15

Review 7.  Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

Authors:  R Sadovsky; G B Brock; S W Gutkin; S Sorsaburu
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

Review 8.  Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility.

Authors:  Eric G Katz; Ronny Bw Tan; Daniel Rittenberg; Wayne J Hellstrom
Journal:  Ther Clin Risk Manag       Date:  2014-08-27       Impact factor: 2.423

9.  Modeling Human Sexual Motivation in Rodents: Some Caveats.

Authors:  Olivia Le Moëne; Anders Ågmo
Journal:  Front Behav Neurosci       Date:  2019-08-27       Impact factor: 3.558

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.